Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Current Pharmaceutical Design|July 16, 2009
ADAM17 as a therapeutic target in multiple diseasesJoaquín Arribas, Cary Esselens
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2021
IFNγ Signaling in Natural and Therapy-Induced Antitumor ResponsesAlex Martínez-Sabadell, Enrique J Arenas, Joaquín Arribas
The Journal of Biological Chemistry|December 16, 2003
The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1Gabriela Velasco-Loyden, Joaquín Arribas, Fernando López-Casillas
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2010
HER2 fragmentation and breast cancer stratificationJoaquín Arribas, Josep Lluís Parra-Palau, Kim Pedersen
Cancers|February 25, 2023
Immunotherapies against HER2-Positive Breast CancerSantiago Duro-Sánchez, Macarena Román Alonso, Joaquín Arribas
Breast Cancer Research : BCR|August 12, 2015
Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescenceBeatriz Morancho, Águeda Martínez-Barriocanal, Josep Villanueva, et al.
Cancer Research|February 24, 2011
p95HER2 and breast cancerJoaquín Arribas, José Baselga, Kim Pedersen, et al.
The EMBO Journal|February 28, 2003
TACE is required for the activation of the EGFR by TGF-alpha in tumorsMaria Borrell-Pagès, Federico Rojo, Joan Albanell, et al.
STAR Protocols|November 1, 2022
Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized miceAlex Martínez-Sabadell, Pablo Ovejero Romero, Joaquín Arribas, et al.
The Journal of Biological Chemistry|January 18, 2007
Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumorsBelén Santiago-Josefat, Cary Esselens, Joan Josep Bech-Serra, et al.
Pageof 9